The most potent antagonist indicated FPR subtype selectivity at 1 μM.
Its selection as the primary therapeutic neurotoxin is due to early animal studies that demonstrated it was the most potent and longest lasting of all subtypes.
Binding studies revealed that some of hydrogen-bond donor containing compounds exhibit improved affinity and selectivity for the α7 nAChR subtype in comparison with most potent metabolite of GTS-21, 3- 4-hydroxy-2-methoxybenzylidene -anabaseine.
Adenosine, through activation of the A2A receptor (A2AR) subtype, ranks among the most potent agents limiting the inflammatory activities of neutrophils.
The most potent compound (3v) showed selectivity over other subtypes of Plk PBDs and inhibited the kinase activity of full-length Plk1.
Introduction of an optimized ω chain to the 5-thiaPG skeleton afforded m-methoxymethyl derivative 33a, which showed the most potent EP4-receptor agonist activity and good subtype-selectivity both in vitro and in vivo.
- BTX- subtype A (BTX-A) is the most potent.
In addition, compound 6b from the tetrahydrobenzo[b]thiophene series presented the most potent and selective CB2 ligand in this series (Ki = 2.15 nM and CB2 subtype selectivity of almost 500-fold over CB1).
Surprisingly, compounds 10a, 11d, 11e and 11f were the most potent and most selective hPPARδ agonists with 104-fold selectivity over the other two subtypes, namely, hPPARα and hPPARγ.
The 1,3-dibutyl derivative of 9- 4- 2- dimethylamino)ethoxy)phenyl)-6,7,8,9- 4- 2- dimethylamino,2-f]purinethoxy phenyl -6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4ntagonist of thethoxy phenyl -6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4btypethoxy phenyl -6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4
